Monogram Orthopaedics, Inc. (MGRM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Monogram Orthopaedics, Inc. (MGRM) trades at $6.00 with AI Score 38/100 (Grade D). Monogram Orthopaedics, Inc. is a medical device company focused on personalized orthopedic implants and robotic surgical equipment. Market cap: $244M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Jun 1, 2026MGRM stock analysis for 2026: Analysts have set a consensus price target of $5.40 for Monogram Orthopaedics, Inc., suggesting 10.0% downside from the current price of $6.00. The AI MoonshotScore is 38/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
MGRM: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Monogram Orthopaedics, Inc. (MGRM) Healthcare & Pipeline Overview
Monogram Orthopaedics is a healthcare company developing robotic surgical equipment and personalized orthopedic implants, aiming to improve precision and outcomes in joint replacement. Their focus on mass-personalized optimization differentiates them in the competitive medical device market, targeting a significant unmet need for tailored surgical solutions.
What Is the Investment Thesis for MGRM?
Monogram Orthopaedics presents a compelling, albeit high-risk, investment opportunity within the orthopedic device market. The company's focus on personalized implants and robotic-assisted surgery addresses a growing demand for improved precision and patient-specific solutions. The potential for enhanced surgical outcomes and reduced revision rates could drive significant adoption of Monogram's technology. However, the company's negative profit margin of -3027.0% and gross margin of -10.4% highlight the challenges of commercializing novel medical technologies. Key catalysts include successful completion of clinical trials and regulatory approvals. The company's small size and limited resources pose risks, but successful execution could yield substantial returns. The beta of 0.69 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
MGRM Key Highlights
- Market capitalization of $244M reflects investor expectations for future growth in the personalized orthopedic implant market.
- Negative profit margin of -3027.0% indicates significant investment in R&D and commercialization efforts, typical for early-stage medical device companies.
- Gross margin of -10.4% suggests that the cost of goods sold currently exceeds revenue, highlighting the need for efficient manufacturing and pricing strategies.
- Beta of 0.69 indicates lower volatility compared to the broader market, potentially appealing to risk-averse investors.
- The company's focus on robotic-assisted surgery and personalized implants positions it to capitalize on the growing demand for precision medicine in orthopedics.
Who Are MGRM's Competitors?
MGRM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings, Inc. | $89.65 | +1.09% | $17.3B | 81 |
| SYK Stryker Corporation | $319.10 | +3.19% | $122B | 80 |
| XVIPY Xvivo Perfusion AB (publ) | $7.13 | +9.00% | $225M | 60 |
| PROF Profound Medical Corp. | $6.85 | -2.00% | $207M | 67 |
| ANIK Anika Therapeutics, Inc. | $14.72 | -1.93% | $196M | 68 |
| BSGM BioSig Technologies, Inc. | $6.10 | +37.08% | $191M | 61 |
| ELMD Electromed, Inc. | $38.18 | -3.39% | $316M | 93 |
| DMTRF 3-D Matrix, Ltd. | $2.50 | +0.00% | $320M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MGRM's Key Strengths?
- Innovative robotic surgical platform.
- Focus on personalized orthopedic implants.
- Potential for improved surgical outcomes.
- Strong intellectual property portfolio.
What Are MGRM's Weaknesses?
- Limited commercialization experience.
- Negative profit and gross margins.
- Small company size and resources.
- Dependence on regulatory approvals.
What Could Drive MGRM Stock Higher?
- Completion of clinical trials for Monogram's robotic surgical system.
- FDA clearance for Monogram's personalized knee implant.
- Expansion of Monogram's intellectual property portfolio.
- Strategic partnerships with leading hospitals and surgical centers.
What Are the Key Risks for MGRM?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Delays in regulatory approvals for Monogram's products.
- Competition from established orthopedic device companies.
- Negative profit and gross margins impacting financial sustainability.
- Dependence on securing additional funding for R&D and commercialization.
What Are the Growth Opportunities for MGRM?
- Expansion into New Orthopedic Applications: Monogram Orthopaedics can leverage its robotic surgery platform and personalized implant technology to expand into other orthopedic applications beyond knee and hip replacements. This includes addressing shoulder, elbow, and ankle joint replacements, representing a significant market opportunity. The global market for shoulder and elbow replacements alone is projected to reach $2.5 billion by 2030, providing a substantial growth avenue for Monogram.
- Strategic Partnerships with Hospitals and Surgical Centers: Collaborating with leading hospitals and surgical centers to integrate Monogram's technology into their orthopedic programs can accelerate adoption and market penetration. These partnerships can provide access to a broader patient base, facilitate clinical trials, and establish Monogram as a preferred provider of personalized orthopedic solutions. Successful partnerships could lead to increased revenue and brand recognition within the medical community.
- Development of Advanced Software and AI Capabilities: Enhancing the software and AI components of Monogram's robotic surgery platform can further improve surgical precision, efficiency, and patient outcomes. This includes developing advanced algorithms for pre-operative planning, real-time surgical guidance, and post-operative monitoring. The integration of AI can also enable predictive analytics to optimize implant design and surgical techniques, creating a competitive advantage for Monogram.
- Geographic Expansion into International Markets: Expanding into international markets, such as Europe and Asia, can significantly increase Monogram's revenue potential. These markets have a growing demand for advanced orthopedic solutions and represent a substantial opportunity for Monogram to establish a global presence. However, international expansion requires navigating regulatory hurdles, adapting products to local market needs, and establishing distribution networks.
- Securing Additional Funding and Investment: Securing additional funding through venture capital, strategic partnerships, or public offerings is crucial for Monogram to support its R&D efforts, clinical trials, and commercialization activities. Adequate funding will enable the company to accelerate the development and launch of its products, expand its sales and marketing efforts, and strengthen its competitive position in the orthopedic device market. The ability to attract and secure funding is essential for Monogram's long-term growth and success.
What Opportunities Does MGRM Have?
- Expansion into new orthopedic applications.
- Strategic partnerships with hospitals.
- Development of advanced software and AI.
- Geographic expansion into international markets.
What Threats Does MGRM Face?
- Competition from established orthopedic device companies.
- Regulatory hurdles and delays.
- Technological obsolescence.
- Economic downturn impacting healthcare spending.
What Are MGRM's Competitive Advantages?
- Proprietary robotic surgical technology.
- Personalized implant design capabilities.
- Patents protecting key innovations.
- First-mover advantage in mass-personalized orthopedics.
What Does MGRM Do?
Monogram Orthopaedics, Inc., incorporated in 2016 and headquartered in Austin, Texas, is dedicated to transforming orthopedic surgery through personalized implants and robotic technology. Originally named Monogram Arthroplasty Inc., the company rebranded in March 2017 to reflect its broader focus on orthopedic solutions. The company is developing a comprehensive product architecture designed to enable mass personalization of orthopedic implants, addressing the unique anatomical needs of each patient. Their core offering includes robotic surgical equipment, related software, orthopedic implants, tissue ablation tools, navigation consumables, and other instrumentation necessary for reconstructive joint replacement procedures. Monogram's robot prototype is engineered to execute precise paths for the insertion of optimized implants into synthetic bone specimens. This technology aims to enhance surgical accuracy and improve implant fit, potentially leading to better patient outcomes and reduced revision rates. The company's approach seeks to move beyond standard, one-size-fits-all implants by creating solutions tailored to individual patient anatomy. By integrating robotics and personalized implant design, Monogram Orthopaedics aims to set a new standard in orthopedic care, offering surgeons advanced tools and patients more effective and durable joint replacements. The company currently has 27 employees.
What Products and Services Does MGRM Offer?
- Develop robotic surgical equipment for orthopedic procedures.
- Design and manufacture personalized orthopedic implants.
- Create software for surgical planning and navigation.
- Produce tissue ablation tools for joint replacement.
- Offer navigation consumables for precise implant placement.
- Provide instrumentation for reconstructive joint replacement procedures.
How Does MGRM Make Money?
- Sales of robotic surgical equipment to hospitals and surgical centers.
- Revenue from the sale of personalized orthopedic implants.
- Recurring revenue from software licenses and updates.
- Sales of navigation consumables used in surgical procedures.
What Industry Does MGRM Operate In?
The medical device industry is experiencing a shift towards personalized medicine and robotic-assisted surgery. The orthopedic implant market is projected to grow, driven by an aging population and increasing demand for joint replacement procedures. Monogram Orthopaedics is positioned to capitalize on these trends with its focus on personalized implants and robotic technology. However, the company faces competition from established players in the orthopedic device market, such as Zimmer Biomet and Stryker, who have greater resources and market share.
Who Are MGRM's Key Customers?
- Hospitals and medical centers performing orthopedic surgeries.
- Orthopedic surgeons specializing in joint replacement procedures.
- Patients requiring joint replacement or reconstructive surgery.
Key Financial Metrics
Return on assets is -85.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.0%, the inverse of the P/E and a quick read on earnings relative to price.
Monogram Orthopaedics, Inc. (MGRM) Valuation Context
Valued at $244M, MGRM is classified as a micro-cap stock. Relative to its peer group, MGRM's quantitative score of 38/100 is below the peer average of 71/100.
Company Profile
Monogram Orthopaedics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Benjamin Sexson. MGRM has traded publicly since 2023.
F-Score 2/9Financial Health
Monogram Orthopaedics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 12.64 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Monogram Orthopaedics, Inc. revenue of about $13.4M for fiscal 2026, with EPS near $-0.08.
MGRM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Monogram Orthopaedics has seen recent insider buying, suggesting confidence from those closest to the company. This is a positive signal, especially in a market where insider selling is more common.
- The community seems optimistic about MGRM's potential to disrupt the orthopedics market with its personalized implants. This narrative is gaining traction.
- There's a growing belief that MGRM's technology could lead to better patient outcomes, which resonates well with socially conscious investors.
- The company’s focus on a niche market (personalized orthopedic implants) could provide a competitive advantage over larger players, similar to how smaller biotech firms sometimes outperform big pharma in specific disease areas.
Bear Case
- Despite the optimism, MGRM is still in the early stages of commercialization. Scaling up production and distribution could present significant challenges.
- Community sentiment can be fickle. Positive buzz doesn't always translate to long-term success, as seen with many meme stocks that have faded.
- The orthopedics market is dominated by established players with deep pockets. MGRM will face intense competition for market share.
- The regulatory pathway for personalized implants could be lengthy and uncertain, potentially delaying market entry and increasing costs. Think of the challenges faced by companies developing novel medical devices.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MGRM Latest News
No recent news available for MGRM.
MGRM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MGRM.
Price Targets
Consensus target: $5.40
MGRM MoonshotScore
What does this score mean?
The MoonshotScore rates MGRM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Benjamin Sexson
CEO
Benjamin Sexson serves as the Chief Executive Officer of Monogram Orthopaedics, Inc. His background includes extensive experience in the medical device industry, with a focus on product development and commercialization. He has a proven track record of leading teams and driving innovation in the orthopedic space. Sexson's expertise spans across engineering, marketing, and business strategy, making him well-suited to guide Monogram Orthopaedics through its growth phase. He is responsible for overseeing all aspects of the company's operations, from research and development to sales and marketing.
Track Record: Under Benjamin Sexson's leadership, Monogram Orthopaedics has focused on advancing its robotic surgical platform and personalized implant technology. He has overseen the development of the company's robot prototype and the expansion of its intellectual property portfolio. Sexson has also been instrumental in securing funding for the company's R&D efforts and establishing strategic partnerships with key stakeholders in the orthopedic industry. His strategic decisions have positioned Monogram Orthopaedics as a leader in personalized orthopedic solutions.
What Investors Ask About Monogram Orthopaedics, Inc. (MGRM) — Healthcare
What does the AI Score mean for MGRM?
MGRM holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Monogram Orthopaedics, Inc. is a medical device company focused on personalized orthopedic implants and robotic surgical equipment. The company aims to revolutionize joint replacement procedures …
What does Monogram Orthopaedics, Inc. do?
Monogram Orthopaedics, Inc. is a medical device company focused on revolutionizing joint replacement surgery through personalized implants and robotic-assisted technology. They are developing a robotic surgical system and patient-specific implants designed to improve surgical precision, implant fit, and patient outcomes.
What do analysts say about MGRM stock?
Analyst coverage of Monogram Orthopaedics (MGRM) is limited, reflecting its small-cap status and early stage of development. Key valuation metrics are difficult to assess due to the company's negative profit margins and limited revenue. However, analysts recognize the potential of Monogram's personalized implant and robotic surgery technology to disrupt the orthopedic device market.
What are the main risks for MGRM?
Monogram Orthopaedics faces several key risks, including regulatory hurdles, competition, and financial sustainability. The company's success depends on obtaining FDA clearance for its robotic surgical system and personalized implants, which can be a lengthy and uncertain process. Monogram also competes with established orthopedic device companies that have greater resources and market share.
What are the key factors to evaluate for MGRM?
Monogram Orthopaedics, Inc. (MGRM) holds an AI score of 38/100 (low). Analysts target $5.40 (-10%). Not financial advice.
How frequently does MGRM data refresh on this page?
MGRM's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MGRM's recent stock price performance?
Monogram Orthopaedics, Inc. (MGRM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative robotic surgical platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MGRM overvalued or undervalued right now?
Monogram Orthopaedics, Inc. (MGRM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $5.40 (-10%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MGRM before investing?
Before investing in Monogram Orthopaedics, Inc. (MGRM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent filings.